Consensus AbbVie Inc. NEO Exchange

Equities

ABBV

CA00288K1084

End-of-day quote NEO Exchange Other stock markets 23:00:00 27/06/2024 BST			5-day change	1st Jan Change
25 ^CAD	+1.46%		+0.36%	+10.28%

06-28	Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU	MT
06-28	AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment	MT

Evolution of the average Target Price on AbbVie Inc.

Price target over the last 5 years

History of analyst recommendation changes

12ae9.hAlV0Fwfl2WfnVvHxk_LCbgkryGZnDTdZXggfVsjCwo.4k4BoChrz1L9_3aQ9H6jOtZgnEnb0VirAgwWMzl2Om7VYGCSN2jOHM3ZGg~d4b182fa6dd6177ea63049a5c49acb8d

Analyst Recommendations on AbbVie Inc.

Piper Sandler Adjusts Price Target on AbbVie to $190 From $185	06-18	MT
AbbVie Says Investors Should Sit Out Tutanota Mini-Tender Offer	06-14	MT
HSBC Upgrades AbbVie to Buy From Hold, Adjusts Price Target to $185 From $161	06-05	MT
ANALYST RECOMMENDATIONS : Abbvie, Air Products, Applied Materials, KLA Corporation, UnitedHealth...	06-05
Cantor Fitzgerald Initiates AbbVie at Overweight Rating With $200 Price Target	05-17	MT
ANALYST RECOMMENDATIONS : Walmart, Netflix, Abbvie, Delta...	05-17
Daiwa Securities Adjusts Price Target on AbbVie to $171 From $190	05-08	MT
BMO Capital Cuts Price Target on AbbVie to $180 From $195, Maintains Outperform Rating	04-29	MT
Morgan Stanley Adjusts AbbVie's Price Target to $191 From $196	04-29	MT
Barclays Adjusts Price Target on AbbVie to $187 From $195	04-29	MT
Deutsche Bank Raises AbbVie's Price Target to $175 Form $170	04-19	MT
Barclays Raises AbbVie Price Target to $195 From $185, Maintains Overweight Rating	03-27	MT
Abbvie Insider Sold Shares Worth $3,716,757, According to a Recent SEC Filing	03-22	MT
Abbvie Insider Sold Shares Worth $10,539,508, According to a Recent SEC Filing	03-21	MT
ANALYST RECOMMENDATIONS : Abbvie, Align Technology; Ulta Beauty, United Airlines, Currys...	03-15
ANALYST RECOMMENDATIONS : AbbVie, Doordash, Eli Lilly, Moderna, Hiscox...	02-26
Mizuho Raises Price Target on Cerevel Therapeutics to $45 From $25 to Reflect Sale Price to AbbVie, Keeps Neutral Rating	02-15	MT
UBS Adjusts Price Target on AbbVie to $172 from $165, Maintains Neutral Rating	02-06	MT
Truist Adjusts Price Target on AbbVie to $195 From $180, Maintains Buy Rating	02-06	MT
Piper Sandler Adjusts Price Target on AbbVie to $185 From $180, Maintains Overweight Rating	02-05	MT
Morningstar Upgrades AbbVie to Hold From Sell, Increases Price Target to $168 From $137	02-05	MT
Wells Fargo Adjusts Price Target on AbbVie to $200 From $180, Maintains Overweight Rating	02-05	MT
Goldman Sachs Adjusts Price Target on AbbVie to $180 From $173, Keeps Buy Rating	02-05	MT
BMO Capital Adjusts Price Target on AbbVie to $195 From $187, Maintains Outperform Rating	02-05	MT
Barclays Adjusts Price Target on AbbVie to $185 From $175, Maintains Overweight Rating	02-05	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

171.5 USD

Average target price

183.2 USD

Spread / Average Target

+6.83%

High Price Target

207 USD

Spread / Highest target

+20.69%

Low Price Target

168 USD

Spread / Lowest Target

-2.05%

Consensus detail

Consensus revision (last 18 months)

Analysts covering AbbVie Inc.

Piper Sandler
HSBC
Cantor Fitzgerald
Daiwa Securities
BMO Capital
Mizuho Securities
Barclays
Deutsche Bank Securities
UBS
Truist Securities
Morningstar
Wells Fargo Securities
Goldman Sachs
Raymond James
William Blair & Co.
BofA Securities
Morgan Stanley
Guggenheim
Argus
Wolfe Research
Atlantic Equities
SVB Securities LLC
Credit Suisse
Societe Generale
Berenberg Bank
JPMorgan Chase
Cowen
Redburn
SVB Leerink
RBC Capital Markets

Ratings for AbbVie Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar